Tirofiban HClThird Party Manufacturing in India

Tirofiban Hydrochloride is a non-peptide glycoprotein IIb/IIIa receptor antagonist that prevents platelet aggregation by blocking the final common pathway of platelet activation. Platelet aggregation is mediated by the binding of fibrinogen to the glycoprotein IIb/IIIa receptor on activated platelets. When platelets are activated by agonists such as ADP, collagen, or thrombin, the GP IIb/IIIa receptor undergoes a conformational change that allows it to bind fibrinogen. Each fibrinogen molecule can bind to GP IIb/IIIa receptors on two different platelets, forming cross-links that build a stable platelet thrombus. Tirofiban selectively and reversibly blocks the GP IIb/IIIa receptor, preventing fibrinogen binding and therefore inhibiting platelet aggregation regardless of the activating stimulus. This makes it one of the most effective antiplatelet agents available, with inhibition of up to 97% of ADP-induced platelet aggregation at therapeutic doses. Tirofiban has a rapid onset of action within 5 minutes and a short half-life of approximately 2 hours, with platelet function recovering within 4 to 8 hours after discontinuation.

Therapeutic Uses

Tirofiban HCl is prescribed for the management of acute coronary syndromes in hospital settings:

• Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): Reduces the rate of thrombotic cardiovascular events including death, myocardial infarction, and refractory ischaemia
• Percutaneous Coronary Intervention (PCI): As an adjunct to reduce thrombotic complications during and after angioplasty and stenting
• Unstable Angina: For high-risk patients undergoing early invasive management
• Acute Myocardial Infarction: Used in combination protocols with aspirin, heparin, and thrombolytic agents

Why Manufacturers Choose Tirofiban HCl

Tirofiban HCl is an essential hospital injectable for cardiac catheterisation labs and critical care units. As a genericised molecule with a strong evidence base from the PRISM-PLUS trials, it has consistent demand from hospital procurement departments across India and export markets. The sterile injection concentrate requires high-quality aseptic manufacturing, positioning it as a value-added product for third party manufacturing partners with lyophilisation and sterile filling capabilities in India.